Daiichi reels at Ranbaxy recall

0
1353
LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link

Japanese drug maker Daiichi Sankyo has encountered fresh challenges related to its acquisition of Indian pharmaceuticals company Ranbaxy. It has already had to endure regulatory setbacks in the US and considerable losses at its newly acquired Indian subsidiary.

The latest in a series of announcements of bad news left Ranbaxy recalling an antibiotic, nitrofurantoin, saying the manufacture of some exports had not met laboratory specifications. According to analysts, the recall will not have a large impact on Ranbaxy’s revenues; however, it will affect the Indian company’s reputation which has already been marred by a series of financial losses and banned products.

In late April, Ranbaxy reported a first-quarter loss of Rs7.61 billion (US$155 million), driven by a US import ban on some of its medications and poor forecasts in relation to the Indian rupee’s movement.

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.

你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章,欢迎成为我们的订阅会员成为我们的订阅会员

已有集团订阅,可点击此处继续浏览。
如对集团订阅感兴趣,请联络我们

LinkedIn
Facebook
Twitter
Whatsapp
Telegram
Copy link